
"I saw a patient who's no longer a patient, and there's nothing better than that."
Where I see patients (1)
Selected research
-
Clinical and molecular characterization of patients with juvenile myelomonocytic leukaemia.
British journal of haematology
-
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells.
Blood
-
Innate immune mechanisms hijacked by leukemia-initiating stem cells for selective advantage and immune evasion in Ptpn11-associated JMML.
Cell reports
Clinical trials
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in...
The proportion will be calculated as the percent of eligible patients who are identified to have an a priori specified genomic or immunophenotypic target and who enroll on at least one of the sub-trials. The corresponding confiden...
Recruiting
More about this studyInotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or...
The response rate will be estimated using the proportion of eligible/evaluable patients with CR/CRi response. A one-sided lower 95% Agresti-Coull confidence limit will be calculated.
Recruiting
More about this studyContact me
Tender wagging care
Our therapy dogs spread joy and smiles at the bedside and throughout the hospital.
Visit Child Life services
